Please Wait.....
Report
Genitourinary Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Interstitial Cystitis, Hematuria, Benign Prostatic Hyperplasia), By Product (Hormonal Therapy, Gynecological, Urologicals, Anti-infectives, others), By Region & Competition, 2020-2030F
Market Report I 2025-03-24 I 180 Pages I TechSci Research
The global Genitourinary Drugs Market was valued at USD 27.80 billion in 2024 and is projected to experience substantial growth throughout the forecast period, with a compound annual growth rate (CAGR) of 2.53% through 2030. The term "genitourinary" (GU) refers to the combined system involving both the genital and urinary organs, which play vital roles in various bodily functions. The genital organs (genitalia) are responsible for sexual and reproductive functions, including the penis, testes, epididymis, vas deferens, prostate gland, and seminal vesicles in males, and the vulva, vagina, cervix, uterus, fallopian tubes, and ovaries in females. The urinary organs facilitate the elimination of waste products in the form of urine, encompassing the kidneys, ureters, bladder, and urethra.
With the aging global population, the prevalence of genitourinary disorders-such as prostate issues, urinary incontinence, and kidney diseases-has risen, driving the demand for genitourinary drugs. For instance, a report by the World Health Organization (WHO) from March 2022 revealed that 491 million people worldwide, aged 15 to 49, are infected with herpes simplex virus type 2 (HSV-2) annually, affecting approximately 13% of the global population in this age group. HSV-2 is a highly prevalent sexually transmitted infection that can result in lifelong infection, causing painful genital sores and increasing susceptibility to other conditions like HIV. This widespread prevalence emphasizes the need for greater awareness, prevention, and effective treatment solutions.
Key Market Drivers:
Advancements in Drug Development
Immunotherapy has emerged as a transformative approach for treating genitourinary cancers, such as renal cell carcinoma and urothelial carcinoma. Immune checkpoint inhibitors, including PD-1 and PD-L1 inhibitors, stimulate the patient's immune system to target and destroy cancer cells. Targeted therapies have shown success in treating genitourinary cancers by blocking specific molecular pathways or receptors involved in tumor growth. For example, tyrosine kinase inhibitors (TKIs) have demonstrated effectiveness in treating renal cell carcinoma.
Further advancements in genomics and molecular biology allow for more precise drug development in the genitourinary space, identifying specific genetic mutations or biomarkers to tailor treatments to an individual's genetic profile. Antibody-Drug Conjugates (ADCs), which deliver cytotoxic agents directly to cancer cells while minimizing damage to healthy tissue, are being developed for urothelial carcinoma and other cancers. The National Institutes of Health (NIH) highlighted the advancements in urothelial carcinoma treatments at the 2023 ASCO-GU Cancers Symposium, underscoring the need for improved treatment strategies as this cancer remains a leading cause of mortality. Hormonal therapies for conditions like prostate cancer are evolving with the introduction of more effective agents that block androgen receptors or reduce testosterone levels. Additionally, combinations of chemotherapy, immunotherapy, and radiation therapy are being explored to enhance treatment outcomes while reducing side effects. For genitourinary infections, the development of next-generation antibiotics with better resistance profiles and fewer side effects is increasingly important due to the growing challenge of antibiotic resistance. Biologic drugs, such as monoclonal antibodies, are also being developed for a range of genitourinary conditions, offering the potential to target specific proteins or immune cells involved in disease progression.
Key Market Challenges:
Generic Competition
As patents for branded genitourinary drugs expire, generic pharmaceutical companies often introduce lower-cost alternatives, leading to significant market competition. This can decrease the market share and profitability of the original drugs, resulting in price reductions. With multiple generic manufacturers entering the market, prices for these generic versions typically decline, which impacts the revenue of the original drug. Branded drugs may experience a rapid decline in market share upon the introduction of generics, which is especially challenging for pharmaceutical companies that rely on a small number of blockbuster genitourinary drugs for revenue. The revenue generated by these blockbuster drugs often funds ongoing research and development efforts for new treatments. When generic competition erodes these revenues, it can hinder a company's ability to invest in innovative drug development. The influx of generics can saturate the market, making it challenging for any single manufacturer to capture a substantial market share. This may lead to price wars and reduced profitability for generic producers. Although generics tend to be more cost-effective, patients and physicians may still favor branded drugs due to perceived efficacy, safety, or familiarity. However, cost considerations may influence patient and physician preferences toward generics.
Key Market Trends:
Rise in Urologic Cancer Therapies
The emergence of targeted therapies has revolutionized the treatment of urologic cancers. Drugs designed to target specific molecular pathways and genetic mutations driving cancer growth have improved the effectiveness of treatments while reducing side effects. Immunotherapies, such as immune checkpoint inhibitors, have shown promising results in treating urologic cancers, particularly renal cell carcinoma and urothelial carcinoma, by enhancing the immune system's ability to target and destroy cancer cells. The combination of immunotherapy, targeted therapies, and traditional chemotherapy has become a standard treatment approach, aiming to maximize treatment efficacy and improve patient outcomes.
Advancements in genomics and molecular diagnostics have enabled personalized treatment approaches, allowing oncologists to tailor urologic cancer therapies to a patient's genetic profile for more effective and targeted treatments. Enhanced screening and diagnostic methods, such as PSA testing for prostate cancer and advanced imaging techniques, have led to earlier detection of urologic cancers, which often results in better treatment outcomes. The pharmaceutical industry continues to invest in the development of novel urologic cancer drugs, expanding the drug pipeline and providing additional treatment options for both patients and healthcare providers.
Key Market Players:
- Abbott Laboratories Ltd.
- Bristol-Myers Squibb Co.
- Novartis AG
- Genentech, Inc.
- F. Hoffmann-La Roche Ltd.
- Ionis Pharmaceuticals, Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Pfizer, Inc.
- AstraZeneca Plc.
Report Scope:
This report segments the global genitourinary drugs market into the following categories and provides an in-depth analysis of industry trends:
- By Indication:
o Prostate Cancer
o Ovarian Cancer
o Bladder Cancer
o Cervical Cancer
o Renal Cancer
o Erectile Dysfunction
o Urinary Tract Infections
o Urinary Incontinence & Overactive Bladder
o Sexually Transmitted Diseases, Interstitial Cystitis
o Hematuria
o Benign Prostatic Hyperplasia
- By Product:
o Hormonal Therapy
o Gynecological Drugs
o Urological Drugs
o Anti-infectives
o Others
- By Region:
o North America: United States, Canada, Mexico
o Asia-Pacific: China, India, South Korea, Australia, Japan
o Europe: Germany, France, United Kingdom, Spain, Italy
o South America: Brazil, Argentina, Colombia
o Middle East & Africa: South Africa, Saudi Arabia, UAE
Competitive Landscape:
The report provides detailed company profiles and analyses of key players in the global genitourinary drugs market.
Available Customizations:
TechSci Research offers customization options for this market report, including a detailed analysis and profiling of additional market players (up to five), tailored to the specific needs of a company.
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Genitourinary Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication (Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Interstitial Cystitis, Hematuria, Benign Prostatic Hyperplasia)
5.2.2. By Product (Hormonal Therapy, Gynecological, Urologicals, Anti-infectives, others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. Asia Pacific Genitourinary Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Product
6.2.3. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Genitourinary Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indication
6.3.1.2.2. By Product
6.3.2. India Genitourinary Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indication
6.3.2.2.2. By Product
6.3.3. Australia Genitourinary Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indication
6.3.3.2.2. By Product
6.3.4. Japan Genitourinary Drugs Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Indication
6.3.4.2.2. By Product
6.3.5. South Korea Genitourinary Drugs Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Indication
6.3.5.2.2. By Product
7. Europe Genitourinary Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Product
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Genitourinary Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By Product
7.3.2. Germany Genitourinary Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By Product
7.3.3. Spain Genitourinary Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.3.2.2. By Product
7.3.4. Italy Genitourinary Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indication
7.3.4.2.2. By Product
7.3.5. United Kingdom Genitourinary Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indication
7.3.5.2.2. By Product
8. North America Genitourinary Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Product
8.2.3. By Country
8.3. North America: Country Analysis
8.3.1. United States Genitourinary Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Product
8.3.2. Mexico Genitourinary Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Product
8.3.3. Canada Genitourinary Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Product
9. South America Genitourinary Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Product
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Genitourinary Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Product
9.3.2. Argentina Genitourinary Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Product
9.3.3. Colombia Genitourinary Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Product
10. Middle East and Africa Genitourinary Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Product
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Genitourinary Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By Product
10.3.2. Saudi Arabia Genitourinary Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By Product
10.3.3. UAE Genitourinary Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By Product
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Genitourinary Drugs Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
16.1. Abbott Laboratories Ltd.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Bristol-Myers Squibb Co.
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products & Services
16.2.4. Financials (In case of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3. Novartis AG
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products & Services
16.3.4. Financials (In case of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4. Genentech, Inc.
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products & Services
16.4.4. Financials (In case of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5. F. Hoffmann-La Rochel Ltd.
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products & Services
16.5.4. Financials (In case of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6. Ionis Pharmaceuticals, Inc.
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products & Services
16.6.4. Financials (In case of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7. Eli Lilly and Company
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products & Services
16.7.4. Financials (In case of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8. Merck & Co, Inc.
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products & Services
16.8.4. Financials (In case of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9. Pfizer, Inc.
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products & Services
16.9.4. Financials (In case of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis
16.10.AstraZeneca Plc.
16.10.1. Business Overview
16.10.2. Company Snapshot
16.10.3. Products & Services
16.10.4. Financials (In case of listed companies)
16.10.5. Recent Developments
16.10.6. SWOT Analysis
17. Strategic Recommendations
18. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security